Leukemia drug shows promise in french compassionate use study
NCT ID NCT03751072
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study looked at how well blinatumomab works and how safe it is in 92 adults with B-cell acute lymphoblastic leukemia that had come back or was not responding to treatment. Patients received the drug through a French compassionate use program. Researchers measured survival, response rates, and side effects to better understand the drug's real-world impact.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
blinatumomab (a drug that helps immune cells attack leukemia cells)
What this could lead to
If results are positive, this could support wider use of blinatumomab for hard-to-treat leukemia patients who have few options.
What could go wrong
This is a retrospective review of a compassionate use program, not a controlled trial. Results may not be as strong as in formal studies, and side effects can be serious.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE LYMPHOBLASTIC LEUKEMIA, IN RELAPSE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
CABANNES-HAMY Aurélie
Paris, 75010, France